학술논문

Clemastine rescues myelination defects and promotes functional recovery in hypoxic brain injury.
Document Type
article
Source
Brain. 141(1)
Subject
Pediatric
Stem Cell Research
Neurodegenerative
Stem Cell Research - Nonembryonic - Non-Human
Neurosciences
Regenerative Medicine
Infant Mortality
Multiple Sclerosis
Perinatal Period - Conditions Originating in Perinatal Period
Brain Disorders
Cerebral Palsy
Autoimmune Disease
Physical Injury - Accidents and Adverse Effects
Aetiology
2.1 Biological and endogenous factors
Neurological
Action Potentials
Animals
Animals
Newborn
Cell Differentiation
Cells
Cultured
Cerebellum
Clemastine
Demyelinating Diseases
Disease Models
Animal
Gene Expression Regulation
Developmental
Histamine H1 Antagonists
Humans
Hypoxia
Brain
Male
Mice
Mice
Knockout
Middle Aged
Myelin Sheath
Oligodendrocyte Precursor Cells
Optic Nerve
Oxygen
Receptor
Muscarinic M1
Recovery of Function
oligodendrocyte
hypoxia
myelination
cerebral palsy
clemastine
Medical and Health Sciences
Psychology and Cognitive Sciences
Neurology & Neurosurgery
Language
Abstract
Hypoxia can injure brain white matter tracts, comprised of axons and myelinating oligodendrocytes, leading to cerebral palsy in neonates and delayed post-hypoxic leukoencephalopathy (DPHL) in adults. In these conditions, white matter injury can be followed by myelin regeneration, but myelination often fails and is a significant contributor to fixed demyelinated lesions, with ensuing permanent neurological injury. Non-myelinating oligodendrocyte precursor cells are often found in lesions in plentiful numbers, but fail to mature, suggesting oligodendrocyte precursor cell differentiation arrest as a critical contributor to failed myelination in hypoxia. We report a case of an adult patient who developed the rare condition DPHL and made a nearly complete recovery in the setting of treatment with clemastine, a widely available antihistamine that in preclinical models promotes oligodendrocyte precursor cell differentiation. This suggested possible therapeutic benefit in the more clinically prevalent hypoxic injury of newborns, and we demonstrate in murine neonatal hypoxic injury that clemastine dramatically promotes oligodendrocyte precursor cell differentiation, myelination, and improves functional recovery. We show that its effect in hypoxia is oligodendroglial specific via an effect on the M1 muscarinic receptor on oligodendrocyte precursor cells. We propose clemastine as a potential therapy for hypoxic brain injuries associated with white matter injury and oligodendrocyte precursor cell maturation arrest.